Alvotech - Ordinary Shares — Cash Flow (NASDAQ:ALVO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Cash from operating activities -312.39 M-312.19 M-236.84 M-50.2 M — Cash from investing activities -63.54 M-46.34 M-18.87 M-104.22 M — Cash from financing activities 424.91 M301.32 M297.31 M270.83 M — Free cash flow -312.39 M-312.19 M-236.84 M-50.2 M —

News

Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products

Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site

Crude Oil Down 3%; XPeng Shares Fall After Q2 Results - XPeng (NYSE:XPEV), Expion360 (NASDAQ:XPON)

Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Movin

Alvotech 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ALVO) 2026-08-21

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates

AbbVie: Strong Q2 And New Catalysts Keep Me Bullish (NYSE:ABBV)

I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade) (NYSE:JNJ)